Uwe Holzwarth

Uwe Holzwarth studied physics and holds a PhD from the University of Stuttgart and a certificate in clinical engineering and clinical radiation protection technology from the University of Kaiserslautern. He joined the JRC in 1997 working on fusion reactor materials and applied nuclear methods in materials science. He was responsible for the JRC’s Scanditronix MC40 cyclotron from 2002 until its shut down in 2014. In this period, he produced medical radionuclides for research projects, investigated the release from biomedical materials using radiotracers, and he pioneered the radiolabelling of industrially manufactured nanoparticles for nanotoxicology studies. In an industry collaboration, using the cyclotron for the nightly production of ¹⁸F, he contributed to the set-up of the first radiopharmaceutical production site in Italy that accomplished in 2004 to obtain all licenses required to distribute ¹⁸F-FDG as ready-to-administer commercial product. He was involved in the set-up and management of the expert panels required by the Medical Device Regulations 2017/745 and 746 in the conformity assessment of high-risk medical devices. After transferring the management of the expert panels to EMA in 2022, Uwe started looking into the obstacles new therapeutic radiopharmaceuticals face to enter clinical practice after obtaining marketing authorisation.

Updated: May 2024